Cancer Family
Skin Neoplasm
CI-CAN-00000051Explore in graph →
Non-malignant347 active trials14 approved drugs74 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000051Explore in graph →
Clinical trials
1,424 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05794035 | Impact of Hypofractionated Radiotherapy Strategy After Surgery of Skin Carcinomas in Older Patients(IMPACTE-01) | recruiting | N/A | 303 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT05518851 | TreAtments and outComes in paTients With prImary CutAneous Lymphoma(TACTICAL) | recruiting | — | 3,000 | Peking University First HospitalOTHER | 1 |
| Nov 18, 2023 |
| clinicaltrials |
| NCT05789043 | Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma | recruiting | Phase 3 | 140 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT05253872 | The MELAcare Study: A New Method for Surveillance of Melanoma Patients | recruiting | N/A | 378 | Herlev and Gentofte HospitalOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT05025813 | Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma(DESQUAMATE) | recruiting | Phase 2 | 27 | Queensland HealthOTHER_GOV | 1 | Aug 1, 2022 | clinicaltrials |
| NCT05157763 | A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 32 | MediWound LtdINDUSTRY | 1 | Dec 15, 2021 | clinicaltrials |
| NCT04331093 | Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma | recruiting | Phase 2 | 40 | Di WuOTHER | 1 | May 26, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Nov 30, 2023source: clinicaltrials